NIPH Clinical Trials Search

JRCT ID: jRCTs051230014

Registered date:13/04/2023

A multicenter single-arm P2 to evaluate safety and efficacy of the total neoadjuvant therapy for cT2 rectal cancer.

Basic Information

Recruitment status Recruiting
Health condition(s) or Problem(s) studiedrectal cancer
Date of first enrollment25/05/2023
Target sample size45
Countries of recruitment
Study typeInterventional
Intervention(s)Neoadjuvant radiation therapy : 5Gyx5 Neoadjuvant chemo therapy : CAPOX (Oxaliplatin 130mg/m2, Capecitabine2000mg/m2/day, d1-14, 3week)x6cycles Operation: Total methorectum excision wiht radical lymph node dissection


Primary OutcomePercentage of pathological complete response (pCR) and percentage of clinical complete response (cCR) (cCR is defined as complete response that has disappeared on imaging)
Secondary OutcomePercentage of radical resection Recurrence form Percentage of local recurrence (NOM:: Non-operative management option) Relapse-free survival (RFS) Overall survival (OS) Preoperative treatment-related adverse event rate as determined by CTCAE ver4.0 Percentage of patients who completed protocol treatment Radiotherapy Completion Rate Completion of chemotherapy Intraoperative safety assessment (intraoperative complications as defined by CTCAE ver4.0) Postoperative safety assessment (CTCAE ver4.0 and postoperative complications as determined by Clavien-Dindo classification), etc. Association of pCR and cCR with the posterior central judgment of MRI

Key inclusion & exclusion criteria

Age minimum>= 20age old
Age maximumNot applicable
Include criteria1. The patient has been fully informed of the contents of the study and has given written consent. 2. The patient has adenocarcinoma of the rectum confirmed by histological examination. 3. No distant metastases are detected on imaging studies, and radical resection is clinically feasible. 4. Age of 20 years or older on the date of consent. 5. ECOG Performance Status (PS) is 0 - 1 (PS 0 for age 71 years or older on the date of consent). 6. Previously untreated rectal cancer with the lower margin of the tumor within 12 cm of the anal verge (AV). 7. Patients with cT2N0M0 in the diagnosis before starting treatment (a lymph node with a short diameter of 7 mm or more is considered positive). The conditions for lymph node metastasis shall be as follows. Contrast-enhanced CT or MRI (plain or contrast-enhanced) with a slice width of 5 mm or less. (i) Short diameter of 10 mm or more (ii) Short diameter of 7 mm or more and one or more of the following a) to c) are met (a) Edge irregularity (b) Low signal area with internal heterogeneity on MRI (c) Circular (long/short diameter ratio < 1.5) If contrast-enhanced CT is not possible due to contrast medium allergy, renal dysfunction, or bronchial asthma, simple CT is acceptable. 8. The following criteria for major organ function within 28 days prior to registration are met. If more than one test result exists within this period, the most recent one should be used. No blood transfusions or hematopoietic factor products should be administered within 28 days prior to the test date. a. Neutrophil count: greater than or equal to 1,500/mm3 b. Platelet count: >= 10.0 x 104 /mm3 c. Hemoglobin concentration: >=9.0 g/dL d. Total bilirubin: 1.5 times or less than the upper limit of the institutional standard e. AST, ALT, ALP: 2.5 times or less than the upper limit of the institutional standard f. Serum creatinine: 1.5 times or less than the upper limit of the institutional standard or creatinine clearance: 45 mL/min or more
Exclude criteria1. underwent treatment by any of the following within a certain period of time prior to initiation of protocol therapy a. extensive surgery (excluding CV port placement) within 4 weeks b. Any anticancer therapy within 4 weeks c. Radiation within 4 weeks 2. concomitant or pre-existing severe pulmonary disease (interstitial pneumonia, pulmonary fibrosis, severe emphysema, etc.) 3. patients who have had a colonic stent implanted 4. patients with serious comorbidities (heart failure, renal failure, liver failure, bleeding peptic ulcer, intestinal paralysis, bowel obstruction, poorly controlled diabetes, etc.) 5. patients with active multiple overlapping cancers (synchronous multiple overlapping cancers or iatrogenic multiple overlapping cancers with a disease-free period of 5 years or less). However, carcinoma in situ (intraepithelial carcinoma) or intramucosal carcinoma that is considered curable by local treatment is not considered active multiple overlapping carcinoma. 6. pregnant or lactating women, positive pregnancy test or unwillingness to use contraception 7. HBs antigen positive or HCV antibody positive. 8. has known human immunodeficiency virus (HIV) infection. 9. otherwise judged by the principal investigator or subinvestigator to be unsuitable for this study.

Related Information


Public contact
Name Atsushi Hamabe
Address Yamadaoka 2-2, Suita, Osaka Osaka Japan 565-0871
Telephone +81-6-6879-3251
Affiliation Osaka University Hospital
Scientific contact
Name Mamoru Uemura
Address Yamadaoka 2-2, Suita, Osaka Osaka Japan 565-0871
Telephone +81-6-6879-3251
Affiliation Osaka University Hospital